Re-branded as Lineage Cell Therapeutics (NYSE US: LCTX)
Ocata Therapeutics
Acquired by Astellas Pharma in 2016 for $379 Million (NY Times’ coverage here)
Re-branded as Lineage Cell Therapeutics (NYSE US: LCTX)
Acquired by Astellas Pharma in 2016 for $379 Million (NY Times’ coverage here)